Addressing the Gap in Rare Liver Disease Care: Ipsen Korea and Advocates Highlight Urgent Needs
Seoul, South Korea – February 26, 2026 – Recognizing World Rare Disease Day, Ipsen Korea, a global mid-sized biopharmaceutical company, hosted a forum on February 25th to raise awareness of rare liver diseases within the country. The event focused particularly on primary biliary cholangitis (PBC), a chronic autoimmune liver disease and the challenges faced by patients transitioning from pediatric to adult care for conditions like biliary atresia. The initiative underscores a growing global effort to improve diagnosis, treatment, and support for individuals living with these often-overlooked conditions. Rare diseases, collectively affecting millions worldwide, present unique hurdles due to limited research, specialized expertise, and often, a lack of public awareness.
The forum brought together representatives from the Korean Rare and Undiagnosed Diseases Association, patient advocacy groups, and medical professionals to discuss the current landscape of rare liver disease care in Korea. A central theme was the significant gap in treatment options and monitoring systems for PBC patients, compounded by a general lack of awareness among the public and even some healthcare providers. This lack of recognition often leads to delayed diagnoses and suboptimal patient outcomes. Ipsen Korea has committed to making PBC awareness a core focus this year, with plans to enhance medical education, leverage data-driven insights, and strengthen collaborations with patient organizations.
The discussion extended beyond PBC to encompass the broader spectrum of rare liver diseases, including progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome, all of which can lead to biliary atresia. These conditions, while individually rare, collectively represent a significant burden for patients and their families. The event highlighted the particularly vulnerable position of children with biliary atresia as they transition from pediatric to adult healthcare systems. Currently, there is a lack of seamless transition protocols, leaving patients at risk of falling through the cracks in care.
The Challenge of Transitioning Care for Biliary Atresia Patients
Biliary atresia, a condition where the bile ducts outside the liver are blocked, often requires surgical intervention in infancy. While surgical success rates have improved, the long-term management of these patients remains complex. According to the Korean Rare and Undiagnosed Diseases Association’s Secretary-General, Bang Hyeonjin, the absence of a structured transition system means that patients often face a dangerous gap in care as they move from pediatric specialists to adult gastroenterologists. “Even with successful surgery, patients demand continuous monitoring and specialized care throughout their lives,” Bang stated. “Without a smooth transition, they risk complications and a diminished quality of life.” This underscores the need for a coordinated, multidisciplinary approach to ensure continuity of care.
The Family Impact of PFIC and the Need for Support
The emotional and practical toll of rare liver diseases extends far beyond the individual patient, impacting entire families. Kim Ji-soo, the representative of the PFIC Patient Advocacy Group, shared the perspective of families living with this genetic disorder. “PFIC isn’t just about one child; it affects the whole family – parents, siblings, everyone,” she explained. “The constant itching, sleep disturbances, and nutritional challenges are hidden struggles that significantly impact daily life. Families need ongoing support and understanding to avoid feelings of isolation.” PFIC, characterized by impaired bile flow within the liver, often requires lifelong management and can lead to significant health complications.
The challenges faced by PFIC families highlight the broader need for increased social awareness and support for those affected by rare diseases. Access to specialized medical care, financial assistance, and emotional support networks are crucial for improving the quality of life for patients and their loved ones. Advocacy groups play a vital role in raising awareness, lobbying for policy changes, and connecting families with resources.
Ipsen Korea’s Commitment to Addressing Unmet Needs
Ipsen Korea’s CEO, Yang Mi-sun, emphasized the company’s commitment to addressing the unmet needs of patients with rare liver diseases. “Rare liver diseases are often invisible, but they profoundly impact the lives of patients and their families,” Yang stated. “PBC, which particularly affects middle-aged women, is often underdiagnosed in Korea, leading to limited treatment options. This year, we will focus on collaborating with patient organizations and medical professionals to drive real change.” Ipsen Korea’s strategy includes expanding medical education programs, utilizing data to better understand disease patterns, and fostering stronger partnerships with patient advocacy groups.
The 2026 World Rare Disease Day slogan, “MORE THAN YOU CAN IMAGINE,” encapsulates the complex realities faced by individuals living with rare conditions. It emphasizes that these diseases are far more than just medical diagnoses; they represent a multifaceted challenge encompassing diagnostic delays, limited treatment access, and a significant burden on patients and families. The slogan serves as a powerful reminder of the need for increased awareness, research, and support.
Looking Ahead: Collaborative Efforts for Improved Outcomes
Ipsen Korea employees expressed their solidarity with the rare disease community, pledging to contribute to reducing isolation and promoting greater understanding. The company plans to continue its efforts to raise social awareness of rare liver diseases and to support data-driven research aimed at improving treatment options and patient outcomes. This includes ongoing collaboration with medical experts and patient advocacy groups to identify and address critical gaps in care.
The focus on PBC and the transition of care for biliary atresia patients represents a crucial step towards improving the lives of those affected by these rare liver diseases. However, sustained commitment from pharmaceutical companies, healthcare providers, policymakers, and the public is essential to ensure that all patients receive the timely diagnosis, appropriate treatment, and ongoing support they deserve. Further research into the prevalence of these conditions in Korea, and the development of tailored care pathways, will be vital in addressing the challenges ahead.
The next step in this collaborative effort will be a series of medical education workshops for gastroenterologists across South Korea, scheduled to commence in April 2026, focusing on the early diagnosis and management of PBC. The Korean Economic Daily reported on the initial plans for these workshops.
What are your thoughts on the challenges faced by those with rare diseases? Share your experiences and insights in the comments below, and please share this article to help raise awareness.
Related reading